March 5, 2026 |
At Age of AI 2026, Inizio Medical’s Phil Wakefield and Inizio Ignite’s Tim Luxford will explore how cross-functional collaboration and AI can unlock faster, more actionable insights across medical and commercial teams. As the pharma landscape grows more complex, organizations that successfully connect field intelligence with strategic decision-making will be best positioned to lead.

In an increasingly complex pharma environment, where access to HCPs is tighter and their time more limited than ever, every interaction must count. By having the ability to share near real-time information and field insights, pharma companies can make sure the right person always shows up to the right HCP and has the right kind of conversation.
To achieve this, medical, field, and commercial teams need to work closer together than they have done historically; more like coordinated account teams – still fully compliant, but better aligned.
The quicker decisions can be made by these teams, through more informed insights, the better. But decision velocity is linked to how well data can move through an organization. Data has to be accessible and structured in a way that lets teams go from field signals to identifying patterns to actionable insight without a lot of manual stitching.
A trend we expect to see more of is a move from siloed, function-owned data to a more strategic insight operating model; one that harmonizes signals across sources, speeds up analysis, and consistently produces decision-ready insights at scale.
It’s here that AI has an important role to play: interpreting data sets, prioritizing specific actions, and informing strategy. AI can also support the capture of data itself, enabling teams to quickly and unobtrusively gather insights from field team and HCP conversations through technologies such as STEM AI, while solutions like HCP Interact help ensure those insights translate into more meaningful, personalized HCP engagement. But while AI is incredibly powerful and is having a big impact on how quickly we can pull insights together, we believe it shouldn’t be the ultimate decision-maker. Despite its advances, AI still lacks the trust, empathy, nuance, and flexibility of humans. Without experts to validate what’s real and add context, risks such as bias, bad inputs, and confidently wrong outputs will persist.
Not losing sight of human input is something we’ve been conscious of at Inizio for a long time. We’ve developed technology platforms, products, and solutions within a unified framework that enables what we call Intelligent Commercialization™ across every stage of the health and life sciences journey. AI underpins a lot of this technology, but human expertise and involvement is always there.
In the future, cross-functional field teams will have a pivotal role to play in the development of commercial strategies and how they’re executed. Their insights, captured during HCP engagements, will feed into the situational analysis phase, provide guidance on target patients and comms topics, and create space for commercial teams to promote their brands.
As those insights become more intelligent, medical will help commercial teams adjust faster and have smarter HCP conversations, which benefits them, benefits the industry – and benefits more patients.
Join us at Age of AI on March 10 in London to hear Tim Luxford and Phil Wakefield explore this topic in more detail and discuss how Intelligent Commercialization™ is transforming field engagement and decision-making.
Read more here.
This content was provided by Inizio
Latest Content from Inizio
We’ve built a new type of health communications consultancy. One that believes in a ‘health first, sector second’ approach. One that connects with every stakeholder. One that blends traditional, digital...
To reflect the importance of self-care in health, we developed and launched a new model for exploring personal health decision-making which provides a framework for strategic planning, whatever the therapy...
Telling a health message is one half of the battle. Ensuring that these messages resonate is another matter entirely. The Lab is our 25-strong, in-house creative and content team within...
Pegasus, the UK’s leading independent health communications consultancy, has had recognition of its work in digital media with shortlistings for four awards at the PM Society Digital Media Awards 2016...
Research findings from our Therapy HCV study shows that 28% of HCV patients in the EU are infected by sharing needles or drug equipment.Our latest market snapshot offers an introduction...
Published in eyeforpharma February 2016 by Rachel Howard
Often a short research study isn’t sufficient to get the level of insights and understanding that you require, especially when working with a hard to reach target audience.It can also...
Living with Rheumatoid Arthritis 2016 is a new syndicated report which offers low-cost, high-value quantitative insight into patient attitudes and behaviour.
We are delighted to welcome Heather Desmet as Head of Living With at the company’s London headquarters.
Effectively communicating research insights is a major focus for today’s market researcher, particularly in global healthcare. It’s not enough now just to present the research evidence. We must tell the...
